The U.S. Dermatological Drugs Market was valued at USD 8.32 billion in 2024, and is projected to reach USD 14.48 billion by 2030, rising at a CAGR of 9.70%. The growth of the market is driven by the availability of novel treatments designed for chronic skin diseases and the increasing prevalence of skin problems such as acne, psoriasis, and others. Increasing awareness regarding the significance of skin health in overall well-being also contributes to the growth.
Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth. In recent years, multiple pharmaceutical and consumer healthcare companies have received U.S. FDA approvals for innovation-based products developed to treat severe skin conditions and enhance patient outcomes.
The emergence of new drug delivery systems and key market participants turning to collaboration-based research efforts in dermatology have also played vital roles in the market's growth. The large number of individuals seeking affordable treatments, the availability of over-the-counter products across retail pharmacies, and retailer service expansions with novel offerings such as fast delivery and online distribution are projected to add lucrative growth opportunities for this market over the forecast period.
This product will be delivered within 1-3 business days.
Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth. In recent years, multiple pharmaceutical and consumer healthcare companies have received U.S. FDA approvals for innovation-based products developed to treat severe skin conditions and enhance patient outcomes.
The emergence of new drug delivery systems and key market participants turning to collaboration-based research efforts in dermatology have also played vital roles in the market's growth. The large number of individuals seeking affordable treatments, the availability of over-the-counter products across retail pharmacies, and retailer service expansions with novel offerings such as fast delivery and online distribution are projected to add lucrative growth opportunities for this market over the forecast period.
U.S. Dermatological Drugs Market Report Highlights
- Psoriasis dominated the therapy segment with more than 35.0% share in 2024, owing to many individuals seeking effective treatment for psoriasis and the focus of market participants on the delivery of novel therapies
- Dermatological drugs for acne are expected to grow at a significant CAGR in the U.S. over the forecast period
- The prescription-based dermatological drugs held the largest market share, 77.5%, in 2024. The over-the-counter segment is anticipated to witness significant growth over the forecast period
- Topical administration dominated the U.S. dermatological drugs market, with a revenue share of 60.0% in 2024, owing to patients' treatment experiences, patient-friendly delivery systems, and ease of use. The parenteral administration segment is expected to witness the fastest CAGR of 10.7% over the forecast period
- Increasing investments in research and development, approvals received for numerous novel therapies and products, and convenience offered by retail pharmacies are contributing to the growth of the U.S. dermatological drugs market.
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19's impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Dermatological Drugs Market Variables, Trends, & Scope
Chapter 4. U.S. Dermatological Drugs Market: Therapy Estimates & Trend Analysis
Chapter 5. U.S. Dermatological Drugs Market: Type Estimates & Trend Analysis
Chapter 6. U.S. Dermatological Drugs Market: Route of Administration Estimates & Trend Analysis
Chapter 7. U.S. Dermatological Drugs Market: Drug Class Estimates & Trend Analysis
Chapter 8. U.S. Dermatological Drugs Market: Distribution Channel Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this U.S. Dermatological Drugs market report include:- AbbVie Inc.
- Pfizer Inc.
- GSK plc.
- LEO Pharma A/S
- Sun Pharmaceutical Industries Ltd.
- GALDERMA
- Amgen Inc.
- Johnson & Johnson Services Inc.
- Novartis AG
- Eli Lilly and Company
- Almirall, S.A
- Bausch Health Companies Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 8.32 Billion |
| Forecasted Market Value ( USD | $ 14.48 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | United States |
| No. of Companies Mentioned | 13 |
